← Guides

MK-677 vs Ipamorelin: oral vs injectable

MK-677 and Ipamorelin are compared constantly because they chase the same physiological goal: stimulating the body's own growth hormone through the ghrelin receptor. But they are very different compounds. The first and most important clarification for studying the topic rigorously is that MK-677 is not a peptide: it is a small, non-peptide molecule taken orally, whereas Ipamorelin is a peptide administered by injection. This guide compares the two at an educational level — what they are, how they act and how they differ — without recommending doses or use. Neither is approved as a medicine for human consumption in most jurisdictions.

Why compare them if one isn't a peptide

Although MK-677 shows up again and again on peptide forums, technically it isn't one. A peptide is a short chain of amino acids; Ipamorelin, for instance, is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2). MK-677 (Ibutamoren) is a small, non-peptide molecule engineered precisely to do what a peptide can't: survive the digestive tract. True peptide GH secretagogues like Ipamorelin are broken down by gut proteases, so they require injection. MK-677, not being an amino-acid chain, resists digestion and is orally bioavailable. They get compared so often because they share the same biological target — the ghrelin receptor — and pursue the same downstream effect: raising endogenous GH and, secondarily, IGF-1. Grasping this distinction is the key to the whole comparison: same target, opposite chemical families and routes of administration.

Same target, different delivery

Both compounds act as agonists of the ghrelin receptor (GHS-R1a), found on pituitary somatotrophs and hypothalamic neurons. By activating that receptor they stimulate pulsatile release of the body's own growth hormone, rather than supplying external GH. Ipamorelin is described in the literature as a 'selective' secretagogue because, in preclinical work, it raised GH without meaningfully increasing ACTH, cortisol or prolactin — unlike earlier peptides such as GHRP-6 or GHRP-2. MK-677 shares the target but, being a long-acting small molecule, produces a more sustained elevation of the GH/IGF-1 axis across the day. The difference isn't in the receptor, which is the same, but in how the compound arrives and how long it keeps that receptor occupied.

Long duration vs short pulsatility

This is the sharpest pharmacological difference. MK-677 has a long half-life: a single oral dose raises GH and sustains IGF-1 for many hours, producing a relatively continuous profile. Ipamorelin, by contrast, is short-acting and pulsatile, closer to the natural physiological pattern of GH spikes; its effect rises and falls relatively quickly. That distinction — sustained versus pulsatile — explains much of their different profiles. In MK-677's controlled trials, chronic elevation of the GH/IGF-1 axis was associated with effects such as increased appetite, fluid retention and edema, joint aches, and — clinically relevant — increased fasting glucose with reduced insulin sensitivity. Ipamorelin has far less human evidence, but as a secretagogue of the same axis it shares theoretical class concerns such as fluid retention and changes in glucose handling. None of these observations is a usage guideline: they describe what was seen in studies, not a recommendation.

Evidence and regulatory status

In quantity of human data, MK-677 is better characterized than most compounds in its market: there are randomized, placebo-controlled trials, including a two-year study in healthy older adults (Nass et al., 2008) that showed increases in fat-free mass but no significant improvement in strength or physical function, alongside the insulin-resistance signal. Ipamorelin's evidence is largely preclinical and early-phase; its most-cited human trial (Beck et al., 2014) tested a different endpoint — postoperative ileus — and did not reach significance on the primary outcome. Despite that difference in data volume, the regulatory status is the same for both: neither is approved by the FDA, EMA or MHRA for human use; both are sold as research chemicals/RUO (research use only) and are not legal to market for human consumption in the US, EU or UK. Both also fall under WADA's scope: growth hormone secretagogues are prohibited in sport. Status varies by jurisdiction and changes, so it should be verified independently.

Frequently asked questions

Is MK-677 a peptide like Ipamorelin?

No. MK-677 (Ibutamoren) is a small, non-peptide molecule with oral bioavailability, whereas Ipamorelin is a peptide (a synthetic pentapeptide) that requires injection. They are compared a lot because they act on the same receptor — the ghrelin receptor (GHS-R1a) — and pursue the same effect: stimulating the body's own GH release. But they belong to different chemical families and are given by opposite routes.

Why is MK-677 taken orally while Ipamorelin is injected?

Because peptides like Ipamorelin are amino-acid chains that gut proteases break down, so they don't survive the oral route and are given by injection. MK-677, not being a peptide but a small molecule, resists digestion and is orally bioavailable. That difference in structure is the reason for their opposite routes of administration.

Is either one approved or legal for human use?

No. Neither MK-677 nor Ipamorelin is approved by the FDA, EMA or MHRA for human use; both are sold as research chemicals/RUO (research use only) and are not legal to market for human consumption in the US, EU or UK. In addition, growth hormone secretagogues are prohibited by WADA in sport. This guide is educational and not medical advice; regulatory status varies by jurisdiction and should be verified independently.

✓ Last reviewed · 2026-07-24